RJT
ALXN

Raymond James Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Raymond James Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,996
Closed -$624K – 1158
2020
Q4 		$624K Buy
3,996
+96
+2% +$12.3K 0.02% 469
2020
Q3 		$446K Buy
3,900
+445
+13% +$48K 0.02% 527
2020
Q2 		$388K Buy
3,455
+795
+30% +$84.4K 0.02% 555
2020
Q1 		$239K Buy
2,660
+636
+31% +$62.4K 0.01% 644
2019
Q4 		$219K Buy
+2,024
New +$216K 0.01% 847
2019
Q3 		– Sell
-2,611
Closed -$342K – 979
2019
Q2 		$342K Buy
2,611
+204
+8% +$26.3K 0.02% 566
2019
Q1 		$325K Sell
2,407
-247
-9% -$30.7K 0.02% 576
2018
Q4 		$259K Sell
2,654
-29
-1% -$3.43K 0.02% 610
2018
Q3 		$373K Buy
2,683
+271
+11% +$34K 0.02% 545
2018
Q2 		$299K Buy
2,412
+80
+3% +$9.35K 0.02% 622
2018
Q1 		$260K Sell
2,332
-361
-13% -$43.1K 0.02% 579
2017
Q4 		$322K Buy
2,693
+561
+26% +$68.3K 0.02% 520
2017
Q3 		$299K Buy
2,132
+456
+27% +$62K 0.02% 535
2017
Q2 		$204K Sell
1,676
-635
-27% -$73.9K 0.02% 661
2017
Q1 		$281K Sell
2,311
-1,424
-38% -$184K 0.02% 520
2016
Q4 		$457K Sell
3,735
-200
-5% -$24.5K 0.04% 375
2016
Q3 		$483K Sell
3,935
-333
-8% -$42.9K 0.04% 344
2016
Q2 		$499K Buy
4,268
+643
+18% +$91.2K 0.04% 331
2016
Q1 		$505K Buy
3,625
+32
+0.9% +$4.7K 0.05% 327
2015
Q4 		$686K Buy
3,593
+2,109
+142% +$368K 0.06% 278
2015
Q3 		$232K Buy
1,484
+271
+22% +$49.4K 0.03% 502
2015
Q2 		$219K Buy
+1,213
New +$209K 0.02% 551
2015
Q1 		– Sell
-1,103
Closed -$204K – 669
2014
Q4 		$204K Sell
1,103
-285
-21% -$52.8K 0.02% 566
2014
Q3 		$230K Buy
+1,388
New +$228K 0.03% 512
2014
Q2 		– Sell
-1,394
Closed -$212K – 635
2014
Q1 		$212K Buy
+1,394
New +$222K 0.03% 512

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Trust's ALXN Position: Q1 2021 in Review

Raymond James Trust sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 3,996 shares — an estimated $624K sold.

Raymond James Trust first reported a position in ALXN in Q1 2014 and held it in 25 quarters. The position peaked at $686K in Q4 2015. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Raymond James Trust reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Raymond James Trust sold 3,996 Alexion Pharmaceuticals shares in Q1 2021, an estimated $624K.
  • Raymond James Trust first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 25 quarters.
  • Raymond James Trust's Alexion Pharmaceuticals position peaked at $686K in Q4 2015.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Raymond James Trust's 13F filing for Q1 2021, filed 3 May 2021.